Applying this technology on the sequenced plasma samples derived from patients with liver cancer or healthy controls, we found that ZNF154 and TLX1 performed with similar sensitivity (20% and 21%, respectively) when forcing the specificity to its maximum level (93% and 94%, respectively). The gene discussed is ZNF154; the disease is liver cancer.